Delving into the Latest Updates on Semaglutide (Novo Nordisk) with Synapse

RegulationPriority Review (United States), Accelerated Approval (United States), Priority Review (China), Breakthrough Therapy (China), Commissioner's National Priority Voucher (United States), Conditional marketing approval (Canada)

Login to view timeline

Structure/Sequence

Sequence Code 50953

Source: *****

This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.

Start Date01 Oct 2028

Sponsor / Collaborator

Ludwig-Maximilians-Universität München

NCT07430332

/ Not yet recruitingPhase 2IIT

Leveraging Semaglutide for Preservation of Beta Cell Function and Restoration of Alpha Cell Function

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Start Date01 Sep 2027

Sponsor / Collaborator

Children's Hospital & Medical Center

NCT06977438

/ Not yet recruitingPhase 4IIT

Promoting Healthy Children and Youth

The rapid emergence of new and highly effective obesity medications has turned the field of pediatric weight management on its head. Adolescents living with obesity, their caregivers, healthcare providers, healthcare systems, policymakers, and payors are now wondering what role health behavior and lifestyle treatment (HBLT) has in terms of body mass index (BMI) reduction, improvements in quality of life and cardiometabolic health, and mitigating nutritional concerns when medications are used. Is intensive (26+ hours) of HBLT needed or could low intensity HBLT be an equally effective alternative; and if so, for whom? Our proposed project will answer these important questions that arise daily in the clinical setting and will generate critical new insights to guide decision-making for teens with obesity and the stakeholders who care deeply about them.

Start Date01 Jan 2027

Sponsor / Collaborator

University of Minnesota

[+2]

100 Clinical Results associated with Semaglutide (Novo Nordisk)

Login to view more data

100 Translational Medicine associated with Semaglutide (Novo Nordisk)

Login to view more data

100 Patents (Medical) associated with Semaglutide (Novo Nordisk)

Login to view more data

373

Literatures (Medical) associated with Semaglutide (Novo Nordisk)

01 Jul 2026·FREE RADICAL BIOLOGY AND MEDICINE

Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis

Article

Author: Zhang, Xin ; Wang, Xinglin ; Huang, Ziteng ; Ye, Xiangming ; Qiao, Gan ; Huang, Ting ; Sun, Weiyue ; Yang, Ping ; Wu, Haoran ; Liu, Yang ; Tang, Linyi ; Li, Liyun

Sarcopenia associated with aging is a significant health issue affecting the quality of life in the elderly, yet research on effective treatments remains insufficient. This study aims to investigate the therapeutic effects and mechanisms of Semaglutide (Sema) in D-gal-induced aging-related sarcopenia and endothelial cell senescence. By establishing D-gal-induced mouse models and human aortic endothelial cells (HAEC), and employing methods such as grip strength tests, ELISA, and immunohistochemistry, the therapeutic efficacy and underlying mechanisms of Sema were systematically evaluated. The results demonstrated that Sema significantly improved grip strength in D-gal-induced mice and reduced serum levels of IL-1β and TNF-α, indicating its protective role against sarcopenia. Furthermore, Sema effectively alleviated endothelial cell senescence and improved endothelial function, with the underlying mechanisms potentially involving the upregulation of SIRT1 expression and inhibition of the cGAS-STING signaling pathway activation. This study systematically reveals, for the first time, the therapeutic potential of Sema in aging-related sarcopenia, especially its protective effect against aortic endothelial senescence, providing new perspectives and evidence for its clinical application.

01 Jun 2026·FREE RADICAL BIOLOGY AND MEDICINE

Semaglutide alleviates age-related dry eye disease by restoring lacrimal gland structure and function

Article

Author: Zuo, Xin ; Wang, Yueying ; Chi, Kaiyi ; Zeng, Hao ; He, Yiru ; Yu, Honghua ; Huang, Zhaohao

The prevalence of age-related dry eye disease (DED) is rapidly increasing with global aging, and progressive lacrimal gland (LG) dysfunction represents a central pathogenic mechanism for which targeted therapies remain limited. Semaglutide (Sema), a glucagon-like peptide-1 receptor agonist widely used in metabolic diseases, has recently shown anti-aging effects in multiple tissues, yet its effects on LG aging and age-related DED have not been defined. Here, using a naturally aged mouse model, we show that long-term Sema treatment significantly alleviates DED-related phenotypes and preserves LG structural integrity. High-throughput single-cell transcriptomic analyses revealed that LG aging was characterized by extensive remodeling of cellular composition, loss of acinar cells, expansion of fibroblasts and immune populations, and enhanced intercellular communication, all of which were broadly attenuated by Sema treatment. SenMayo-based profiling demonstrated widespread accumulation of senescent cells across epithelial, stromal, and immune compartments, accompanied by activation of stress-, inflammatory-, and apoptotic transcriptional programs. Sema markedly reduced senescent cell burden and senescence-associated transcriptional activation, consistent with decreased SA-β-gal activity, p21 expression, and SASP-related factors in LGs, and reduced systemic inflammatory cytokines. Mechanistically, Sema exerted cell-type-specific effects by alleviating oxidative stress and enhancing stress adaptation in acinar cells, suppressing extracellular matrix remodeling and pro-fibrotic programs in fibroblasts, and dampening pro-inflammatory and chemotactic activation in macrophages. Together, these findings demonstrate that Sema mitigates age-related LG dysfunction and DED through coordinated attenuation of senescence-associated pathological programs, supporting cellular senescence as a pharmacologically tractable mechanism and highlighting Sema as a potential therapeutic strategy for age-related DED.

01 Jun 2026·JACC-Basic to Translational Science

Semaglutide Reverses Ectopic Lipid Accumulation, Impaired Myocardial Perfusion Reserve, and Diastolic Dysfunction in a Mouse Model of Cardiometabolic Heart Disease

Article

Author: Epstein, Frederick H ; Quach, Kenny ; Saleh, Nemati R ; Patel, Amit R ; Bresticker, Julia E ; Wolf, Matthew J ; Pavelec, Caitlin M ; Skacel, Thomas P ; Bradley, Leigh A

Semaglutide (SEMA) improves cardiometabolic outcomes in obesity, but its mechanisms remain incompletely understood. We examined the effects of SEMA in mice fed a high-fat, high-sucrose diet. Obese mice were treated with SEMA and compared with pair-fed controls to account for reduced dietary intake with SEMA. Multiparametric cardiovascular magnetic resonance was used to assess epicardial adipose tissue volume and composition, myocardial fat fraction, adenosine myocardial perfusion reserve, systolic strain, and diastolic function, with histological evaluation of myocardial fibrosis. SEMA treatment reduced proinflammatory epicardial adipose tissue, reduced ectopic lipid accumulation, improved myocardial perfusion reserve, and reversed impairments in systolic and diastolic strain, whereas pair-feeding did not. Myocardial fibrosis was also reduced with SEMA treatment. These results indicate that SEMA reverses key CMR and histological features of obesity-induced cardiometabolic heart disease in mice, independent of changes in dietary intake.

3,041

News (Medical) associated with Semaglutide (Novo Nordisk)

28 May 2026

·www.prnewswire.com

Parker Waichman LLP Files Lawsuit on behalf of Florida Resident Alleging Development of Irreversible Eye Condition, NAION, after taking Ozempic and Mounjaro

Parker Waichman, a national law firm, has now filed multiple lawsuits where each Plaintiff alleges that he or she developed NAION after taking Novo Nordisk's Ozempic or Wegovy and/or Eli Lilly's Mounjaro or Zepbound. PORT WASHINGTON, N.Y., May 28, 2026 /PRNewswire/ -- Parker Waichman has now filed multiple lawsuits on behalf of victims who were prescribed Ozempic, Wegovy, Mounjaro and/or Zepbound and developed NAION, an irreversible eye condition that causes partial or complete permanent vision loss in one or both eyes. Most recently, on May 20, 2026, the Firm filed a lawsuit on behalf of a Florida resident who developed NAION after taking Ozempic and Mounjaro. See Sparage v. Novo Nordisk Inc., et al. Docket No: 2:26-cv-03450. Parker Waichman continues to file additional cases and urges individuals who have suffered serious eye injuries after taking these widely prescribed GLP-1 receptor agonist medications to contact them for a free case review. These medications, originally developed to treat Type 2 diabetes, have surged in popularity for weight loss. However, recent studies have uncovered a disturbing link between semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound) and NAION, a condition that causes permanent vision loss by cutting off blood flow to the optic nerve. Patients who took these drugs have reported sudden blindness, optic nerve damage, and other irreversible complications, raising concerns about the failure of drug manufacturers to warn consumers and medical professionals about these risks. A 2025 study published in JAMA Ophthalmology examined nine patients who developed optic nerve disorders after using GLP-1 medications, with the majority suffering from NAION-like symptoms. Additional research from Harvard's Mass Eye and Ear Institute found that diabetic users of semaglutide were four times more likely to develop NAION, while non-diabetic users taking the drug for weight loss faced a sevenfold increased risk. Despite growing scientific evidence, Novo Nordisk continues to downplay the dangers associated with these medications, failing to include adequate warnings about the risk of permanent blindness. Parker Waichman LLP Fights for Victims Nationwide "NAION is a devastating, and permanent, eye injury diagnosis. Studies from multiple, reputable institutions, have shown a statistically significant relationship between semaglutide (the active ingredient in Ozempic and Wegovy) and NAION as well as tirzepatide (the active ingredient in Mounjaro and Zepbound) and NAION. Despite this evidence, Novo Nordisk and Eli Lilly continue to deny reality by failing to warn consumers and medical professionals about this horrific injury and must be held accountable," said Jason S. Goldstein, Senior Litigation Counsel at Parker Waichman LLP. Parker Waichman LLP is currently accepting cases nationwide for individuals who have suffered vision loss, blindness, or serious optic nerve damage after taking Ozempic, Wegovy, Mounjaro or Zepbound. Victims may be entitled to compensation for medical expenses, lost wages, pain and suffering, and other damages. Free Case Review for Affected Individuals If you or a loved one experienced sudden vision loss, blindness, or optic nerve damage after using Ozempic, Wegovy, Mounjaro or Zepbound, you may have a legal claim against the drug manufacturers. Parker Waichman LLP is offering free, no-obligation case evaluations to help victims understand their rights and pursue justice. Contact Parker Waichman LLP Today For a free consultation, call 1-800-YOUR-LAWYER (1-800-968-7529) or visit YourLawyer.com to learn more about your legal options and how to protect your rights. About Parker Waichman LLP Parker Waichman LLP is a nationally recognized law firm dedicated to fighting for victims of defective drugs, dangerous products, accidents, and corporate negligence. Specifically, the Firm is quite experienced in representing eye injury victims due to the negligence of pharmaceutical companies. Representative cases include In Re Elmiron (Pentosan Polysulfate Sodium) Products Liability Litigation and Bausch & Lomb Contact Lens Solutions Prod. Liab. Litig. With a proven track record of holding pharmaceutical companies accountable, the firm has secured billions in settlements and verdicts for injured clients. Media Contact: Jason Goldstein Phone: 516-466-6500 Email: [email protected] SOURCE Parker Waichman LLP 21% more press release views with Request a Demo

Patent Infringement

28 May 2026

·www.globenewswire.com

Felix Offers Ozempic at Generic-Level Pricing as Lower-Cost GLP-1 Demand Remains Elevated Across Canada

Eligible patients can access Ozempic savings through Felix, alongside continued access to Apo-Semaglutide Felix launches Get Started for Free, waiving the initial $99 clinician visit fee at launch; patients pay $149/month with free delivery and ongoing clinical support included, and no monthly subscription feeFelix platform data shows sustained patient demand nearly one week after an initial ~14x surge in submitted clinician weight-loss visit requests TORONTO, May 28, 2026 (GLOBE NEWSWIRE) -- Felix Health, Canada’s largest virtual weight-loss clinic and a leading online health platform, has expanded its lower-cost GLP-1 offering for Canadians, with eligible patients now able to receive Ozempic at generic-level pricing through Novo Nordisk’s savings program. Felix will also continue offering Apo-Semaglutide, Apotex’s generic semaglutide product. Felix’s monthly pricing is $149/month across Canada, including free delivery and ongoing clinical support, with no mandatory monthly subscription required to access that price. The company is also launching Get Started for Free, waiving the initial visit fee at launch to reduce upfront costs for patients starting care. Affordability has been a real barrier for patients, particularly those paying out of pocket. Nearly one in four Felix patients taking semaglutide who discontinued in the last year cited cost as the primary reason. Since launching lower-cost access, Felix saw submitted clinician weight-loss visit requests reach roughly 14x typical daily volumes in the first 24 hours, with 62% from new patients and 38% from existing or returning patients. Nearly one week later, patient requests remain well above pre-launch volumes, showing sustained demand beyond the initial launch surge. “Lower-cost GLP-1 options are good news for patients, especially those who have been paying out of pocket,” said Tracey Phillips, Chief Pharmacy Officer at Felix Health. “But access is about more than price. Felix data shows that 71% of weight-loss patients use clinical or pharmacy support within the first 90 days. Those first weeks and months of treatment often come with questions about dosing, side effects, refills and follow-up.” “Within hours, we saw that lower-cost access was already changing Canadian patient behaviour,” said Kyle Zien, co-founder and CEO of Felix Health. “People are moving quickly when the cost barrier comes down. As more GLP-1 options enter the market, patients need to compare the full picture: the monthly cost, what support is included and how care continues after the prescription.” Felix’s model combines online assessment, clinician review, appropriate prescribing, pharmacy coordination, free delivery and ongoing clinical care, including dose-related support and side-effect guidance. The company is also piloting same-day delivery in the GTA, part of Felix’s broader focus on making lower-cost care easier to access and easier to navigate. About Felix Health Founded in 2019, Felix is a leading Canadian digital healthcare company and Canada’s largest weight loss clinic. Trusted by more than 1.5 million Canadians, Felix provides online assessments, treatment plans, prescription delivery and ongoing care across weight management and other everyday health categories, including menopause, sexual health, acne, hair loss, and longevity biomarker testing. Learn more at felixforyou.ca Media Contact: Livy Jacobs for Felix Healthlivyjacobs@livpr.com

28 May 2026

·firstwordpharma.com

CVS reopens door to Lilly's Zepbound, adds newly launched Foundayo

Eli Lilly looks poised to stretch its lead over Novo Nordisk in the obesity space after CVS Caremark said Thursday it would restore coverage of the US pharma's weight-loss injection Zepbound (tirzepatide) and begin covering its newly launched oral offering Foundayo (orforglipron) on standard commercial formularies serving millions of Americans.Last year, CVS had struck a deal to make Novo's competing GLP-1 drug Wegovy (semaglutide) the preferred obesity treatment on its standard formularies, while excluding Zepbound.Beginning June 1, CVS says it will remove a new-to-market block on Foundayo, Lilly’s once-daily oral GLP-1 drug that was approved in April. Meanwhile, broader coverage for Zepbound will return across template plans as an additional preferred option on Oct. 1 (see – Physician Views Preview: Finding Foundayo's place in burgeoning oral obesity space).According to Lilly, eligible commercially insured patients could pay as little as $25 a month for their medicine, while Medicare Part D beneficiaries may also qualify to pay $50 per month through the company's GLP-1 Bridge programme beginning in July.With the Caremark update, Lilly noted that its full obesity medicine portfolio will now be covered by all three of the largest pharmacy benefit managers (PBMs) in the US.For its part, Novo said it was "pleased" that injectable and oral versions of Wegovy will keep their preferred status on CVS's formularies, adding that CVS patients can remain on those drugs "without interruption." The Danish drugmaker recently said its Wegovy Pill, which was approved late last year, is off to a record-breaking start in the US (see – Vital Signs: Novo Nordisk's tussle with Eli Lilly changes venue).Together, the changes put Lilly and Novo on more equal footing across one of the country’s largest PBMs, whose standard formulary templates represent coverage for roughly 25 million to 30 million Americans.CVS said it expects the formulary changes to generate increased savings in the weight-management category after earlier efforts to pressure manufacturers on pricing. The PBM described last year's decision to prioritise Wegovy as part of a push "to bend the cost curve" for obesity drugs through negotiations with manufacturers."By acting early, we helped improve affordability and get ahead of a rapidly evolving GLP-1 pipeline," CVS said Thursday. "This past year, as this therapy class has continued to evolve, we worked with the manufacturers to secure a more affordable cost."CVS noted that plan sponsors adopting its template formularies will still retain discretion over whether to cover GLP-1 medicines, so the broader formulary inclusion doesn't automatically guarantee patient access.

Drug Approval

100 Deals associated with Semaglutide (Novo Nordisk)

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D10025	Semaglutide (Novo Nordisk)	A10BJ06	DB13928

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Heart Diseases	United Kingdom	Novo Nordisk A/S	01 Apr 2026
Fibrosis, Liver	United States	Novo Nordisk, Inc.	22 Dec 2025
Pulmonary Fibrosis	Canada	Novo Nordisk Canada, Inc.	21 Dec 2025
Cardiovascular Diseases	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk, Inc.	15 Aug 2025
Metabolic Dysfunction Associated Steatohepatitis	United States	Novo Nordisk A/S	15 Aug 2025
Chronic Kidney Diseases	United States	Novo Nordisk, Inc.	28 Jan 2025
Chronic Kidney Diseases	United States	Novo Nordisk A/S	28 Jan 2025
Stroke	Australia	Novo Nordisk Pharmaceuticals Pty Ltd.	16 Dec 2024
Myocardial Infarction	Canada	Novo Nordisk Canada, Inc.	27 Nov 2024
Obesity	United States	Novo Nordisk, Inc.	04 Jun 2021
Overweight	United States	Novo Nordisk, Inc.	04 Jun 2021
Diabetes Mellitus, Type 2	United States	Novo Nordisk, Inc.	05 Dec 2017

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Albuminuria	Phase 3	Canada	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Germany	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Netherlands	Novo Nordisk A/S	14 Mar 2022
Albuminuria	Phase 3	Spain	Novo Nordisk A/S	14 Mar 2022
Osteoarthritis, Knee	Phase 3	United States	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Canada	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Colombia	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Denmark	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	France	Novo Nordisk A/S	01 Oct 2021
Osteoarthritis, Knee	Phase 3	Norway	Novo Nordisk A/S	01 Oct 2021

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05813925 (REDEFINE 5, Pubmed \| Lancet Diabetes Endocrinol)	Phase 3	Overweight	331	Cagrilintide-semaglutide	matsoddyzk(uenlcydsib) = oxarcfjlfw dhjcevnwjw (houkvswigk )	Positive	01 Jun 2026
				Semaglutide	matsoddyzk(uenlcydsib) = gefutfmnvj dhjcevnwjw (houkvswigk )
NCT06041217 (STEP12, CTgov)	Phase 3	Obesity	242	Placebo	spghtoaesu(nerrxjywrp) = txvvnjavle hmfkuogmbc (ddkybaulie, 5.4) View more	-	18 May 2026
NCT05514535 (CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	573	Semaglutide+Insuline glargine U100 (reduced) (Insuline Glargine U100 (Reduced) + Semaglutide)	sphjxtvedn(thjmnnyeqt) = clizwurqmd qawblfxtqd (wbexikcxnk, 0.84) View more	-	11 May 2026
				Insuline glargine U100 (titrated) (Insuline Glargine U100 (Titrated))	sphjxtvedn(thjmnnyeqt) = slhkqzibrk qawblfxtqd (wbexikcxnk, 0.92) View more
NCT05035095 (OASIS 1, CTgov)	Phase 3	Obesity	667	Semaglutide (Oral Semaglutide 50 mg)	ceggoghjln(xuwewiwcjh) = uydbmbexlm ldxzahcqxq (whxetshjyg, 10.3) View more	-	07 May 2026
				placebo+semaglutide (Placebo)	ceggoghjln(xuwewiwcjh) = elezevoenl ldxzahcqxq (whxetshjyg, 7.2) View more
NCT03914326 (SOUL, Pubmed \| JAMA Cardiol)	Phase 3	Diabetes Mellitus, Type 2	9,650	Oral Semaglutide	njebfvlepa(elxcinnhbt) = xohrnhqwyw rnmywgdgee (osdbjopqke, 1.01 - 1.02) View more	Positive	01 May 2026
NCT05649137 (STEP UP T2D, CTgov)	Phase 3	Diabetes Mellitus, Type 2 \| Obesity	512	Semaglutide (Semaglutide 7.2 mg)	thlnbhubix(hkpfhjenyk) = bgnftduumi yfwusauqas (dfsudkiqrv, 8.7) View more	-	27 Apr 2026
				Semaglutide (Semaglutide 2.4 mg)	thlnbhubix(hkpfhjenyk) = wsulocgdyc yfwusauqas (dfsudkiqrv, 8.1) View more
NCT05646706 (STEP UP, CTgov)	Phase 3	Obesity	1,407	Semaglutide (Semaglutide 7.2 mg)	vudworscaw(fhsaxbnhre) = xrbosnuitp dfnhekddtm (owfoqzhxec, 10.6) View more	-	23 Apr 2026
				Placebo (Placebo)	vudworscaw(fhsaxbnhre) = tyudirfvnc dfnhekddtm (owfoqzhxec, 7.1) View more
NCT05144984 (CTgov)	Phase 2	Diabetes Mellitus, Type 2	500	Placebo (NNC080-0389)+Semaglutide	mfojieprnw(hjvmkelrgx) = lfxzfoudzc ncbzdzvrcz (vphifexpvl, 0.9) View more	-	09 Apr 2026
NCT05564117 (OASIS 4, CTgov)	Phase 3	Obesity	307	Semaglutide	iwofzbautj(ticwmslwpt) = uynwvblhdg vtmkqbefju (vstdlcxxba, 10.5) View more	-	25 Feb 2026
NCT05891496 (CTgov)	Phase 3	Alzheimer Disease	23	Semaglutide (Semaglutide)	uwrnmhqolb(jcjufyzfyh) = uxermuprrs qfxpfsurvx (xkhrlmefuj, 29.68) View more	-	24 Feb 2026
				placebo+semaglutide (Placebo)	uwrnmhqolb(jcjufyzfyh) = eqofhhymey qfxpfsurvx (xkhrlmefuj, 25.70) View more

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.

login

or

view full example data

Understand key drug designations in just a few clicks with Synapse.

Semaglutide (Novo Nordisk)

Overview

Basic Info

Structure/Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation